MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.110
+0.290
+10.28%
Closed 16:00 10/21 EDT
OPEN
2.830
PREV CLOSE
2.820
HIGH
3.150
LOW
2.830
VOLUME
52.57K
TURNOVER
--
52 WEEK HIGH
13.23
52 WEEK LOW
2.750
MARKET CAP
51.19M
P/E (TTM)
-2.0538
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SBPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SBPH News

  • The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe
  • Benzinga.3d ago
  • Stocks That Hit 52-Week Lows On Thursday
  • Benzinga.4d ago
  • Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
  • GlobeNewswire.4d ago
  • The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
  • Benzinga.10/08 11:11

More

Industry

Biotechnology & Medical Research
+1.34%
Pharmaceuticals & Medical Research
+0.39%

Hot Stocks

Name
Price
%Change

About SBPH

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
More

Webull offers Spring Bank Pharmaceuticals Inc (SBPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.